AC Immune SA
ACIU · XNASCIK 1651625fmd_0FXX64E155P4JM0KT355XXSQKXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 23 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 23 | 20 | 7 | 110 | 15 | 0 | 4 | 15 | 27 | 4 |
| Research and development | 26 | 33 | 44 | 50 | 59 | 62 | 60 | 55 | 63 | 56 |
| Selling, general and administrative | 8 | 10 | 12 | 16 | 19 | 18 | – | – | – | – |
| Operating income | (10) | (23) | (50) | 45 | (61) | (79) | (71) | (54) | (52) | (69) |
| Interest expense | – | – | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Income before taxes | (7) | (26) | (51) | 45 | (62) | (73) | (71) | (54) | (51) | (70) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (7) | (26) | (51) | 45 | (62) | (73) | (71) | (54) | (51) | (70) |
| Net income | (7) | (26) | (51) | 45 | (62) | (73) | (71) | (54) | (51) | (70) |
| Net income to common shareholders | – | – | – | – | (62) | (73) | (71) | (54) | (51) | (70) |